BMI View: Despite the geopolitical uncertainty rising from the Russian intervention in Kiev, we believe
that Moldova's healthcare and pharmaceutical market will continue to grow in 2014 as the economy
continues to improve. This is because Moscow's intervention in Ukra ..."
BMI View: Moldova's economy has gone from strength to strength in 2013 following a terrible 2012 and
this return to growth bodes well for the pharmaceuticals and healthcare market. Politicians have their eyes
firmly set on Europe, with the biannual Eastern Partnership ..."
BMI View: Moldova started the year on a shaky footing, with a political crisis and the shadow of H212's recession hanging over the government. Now that a sense of stability is returning, politicians can focus on mapping out Moldova's future within the EU - which would have widesp ..."
BMI View: Moldova will not witness a sudden influx of multinational drugmakers. Combined with limited
public sector healthcare resources, its low per capita incomes and thus pharmaceutical spending will
continue to provide few opportunities for research-based pharmaceutical man ..."
BMI View: We continue to view Moldova as one of the least attractive emerging Europe markets for multinational companies. Per capita spending on medicines is low, on account of modest incomes, with government spending also representing less than half of the country's total health ..."
Given the high level of reliance on out-of-pocket payments, the growth of the Moldova's pharmaceutical market is expected to be shaped by the prevailing economic conditions, both at home and abroad, on account of the importance of remittances to the country's GDP. For 2012, we ex ..."
BMI View: Given the high level of reliance on out-of-pocket payments, the growth of the Moldova's
pharmaceutical market is expected to be shaped by the prevailing economic conditions, both at home and
abroad, on account of the importance of remittances to the country's GDP. For ..."